Immunocryosurgery for non-superficial basal cell carcinoma: a pro-spective, open-label phase III study for tumours ≤ 2 cm in diameter.

Cryosurgery and topical imiquimod are established mono-therapies for superficial basal cell carcinoma (BCC) but are often insufficient for thicker BCCs. We present here a phase III, prospective, interventional, single-arm (cases only) study (trial registration: NCT01212562) to evaluate the feasibility and efficacy of cryosurgery (liquid nitrogen, open spray, 2 × 15 s; day 14) during 5 weeks' imiquimod ("immunocryosurgery") for primary, non-superficial BCC, ≤ 2 cm in diameter. Ninety-one consecutive patients with 134 basal cell carcinoma were evaluated. A total of 83 patients (124 tumours) started treatment, and 79 patients (119 tumours) completed at least one cycle of immunocryosurgery (feasibility: 95.2%; follow-up: 18-60 months). The efficacy after one treatment cycle was 95 ± 2% stable complete remissions (116/119 tumours cleared, 3/116 tumours relapsed: 6 treat-ment "failures"). Neither tumour size (p = 0.865) nor localization (p = 0.233) predicted outcome. Repeat immunocryosurgery controlled 5/6 treatment failures (overall efficacy: 99%). Lack of a conventionally treated control group is a limitation of this study. However, the results show a high therapeutic efficacy of immunocryosurgery in a large series of primary non-superficial BCC.

[1]  C. Kalogeropoulos,et al.  Imiquimod can be combined with cryosurgery (immunocryosurgery) for locally advanced periocular basal cell carcinomas , 2011, British Journal of Ophthalmology.

[2]  M. Weinstock,et al.  Predictors of basal cell carcinoma in high-risk patients in the VATTC (VA Topical Tretinoin Chemoprevention) trial. , 2012, The Journal of investigative dermatology.

[3]  S. van der Geer,et al.  Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study , 2012, The British journal of dermatology.

[4]  H-S Yoon,et al.  Method of assessing involved facial areas: rule of fours , 2008, The British journal of dermatology.

[5]  A. Crowson,et al.  Basal cell carcinoma: biology, morphology and clinical implications , 2006, Modern Pathology.

[6]  M. Jansen-Vullers,et al.  One‐stop‐shop treatment for basal cell carcinoma, part of a new disease management strategy , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[7]  E. Nagore,et al.  A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  C. Garbe,et al.  A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. , 2007, Journal of the American Academy of Dermatology.

[9]  L. Cleaver.  Prevalence of a History of Skin Cancer in 2007: Results of an Incidence-Based Model , 2011 .

[10]  I. Bassukas,et al.  Combination of cryosurgery and topical imiquimod: does timing matter for successful immunocryosurgery? , 2009, Cryobiology.

[11]  Gail M. Williams,et al.  Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. , 2009, The Journal of investigative dermatology.

[12]  P. Parekh,et al.  Imiquimod 5% Cream as Adjunctive Therapy For Primary, Solitary, Nodular Nasal Basal Cell Carcinomas Before Mohs Micrographic Surgery: A Randomized, Double Blind, Vehicle‐Controlled Study , 2009, Dermatologic Surgery.

[13]  E. Kliewer,et al.  Trends of nonmelanoma skin cancer from 1960 through 2000 in a Canadian population. , 2005, Journal of the American Academy of Dermatology.

[14]  E. Christensen,et al.  High and sustained efficacy after two sessions of topical 5‐aminolaevulinic acid photodynamic therapy for basal cell carcinoma: a prospective, clinical and histological 10‐year follow‐up study , 2012, The British journal of dermatology.

[15]  C. Vlachos,et al.  Immunocryosurgery for patients with therapeutically challenging basal cell carcinomas: Report of two representative cases , 2012, The Journal of dermatological treatment.

[16]  M. Kasper,et al.  Basal cell carcinoma - molecular biology and potential new therapies. , 2012, The Journal of clinical investigation.

[17]  S. Shumack,et al.  Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. , 2002, Archives of dermatology.

[18]  Carmen D Dirksen,et al.  Surgical excision vs Mohs' micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial , 2004, The Lancet.

[19]  E. Alexopoulos,et al.  Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open‐label study of cryosurgery during continued imiquimod application , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[20]  J. Harvey,et al.  Recurrence rates of basal cell carcinoma of the periocular skin: what to do with patients who have positive margins after resection. , 2012, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[21]  E. Alexopoulos,et al.  Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. , 2011, European journal of dermatology : EJD.

[22]  D. Ratner,et al.  The role of targeted molecular inhibitors in the management of advanced nonmelanoma skin cancer. , 2011, Seminars in cutaneous medicine and surgery.

[23]  L. Schouten,et al.  A systematic review of treatment modalities for primary basal cell carcinomas. , 1999, Archives of dermatology.

[24]  P. Buettner,et al.  Risk factors for surgical site infection after dermatological surgery , 2012, International journal of dermatology.

[25]  K. Jurczyszyn,et al.  The application of Levulan®-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma , 2012, Medical science monitor : international medical journal of experimental and clinical research.

[26]  S. Tucker,et al.  Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy. , 2006, Journal of the American Academy of Dermatology.

[27]  D. Macfarlane,et al.  Cryoimmunotherapy: superficial basal cell cancer and squamous cell carcinoma in situ treated with liquid nitrogen followed by imiquimod. , 2011, Archives of dermatology.